Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age

Next Previous
Trial Profile

A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human Papillomavirus 9-valent recombinant vaccine Merck (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

  • 02 Jun 2026 Planned End Date changed from 31 Mar 2028 to 30 Nov 2029.
  • 16 Nov 2020 Planned End Date changed from 1 Feb 2027 to 31 Mar 2028.
  • 16 Nov 2020 Planned primary completion date changed from 1 Feb 2027 to 31 Mar 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top